Lipocine Inc. (LPCN): Price and Financial Metrics

Lipocine Inc. (LPCN): $0.82

0.00 (0.38%)

POWR Rating

Component Grades














  • Sentiment is the dimension where LPCN ranks best; there it ranks ahead of 98.73% of US stocks.
  • LPCN's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • LPCN ranks lowest in Momentum; there it ranks in the 12th percentile.

LPCN Stock Summary

  • LPCN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 206.12 -- higher than 87.95% of US-listed equities with positive expected earnings growth.
  • With a year-over-year growth in debt of -58.66%, Lipocine Inc's debt growth rate surpasses only 5.69% of about US stocks.
  • Revenue growth over the past 12 months for Lipocine Inc comes in at 29,250.18%, a number that bests 99.91% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Lipocine Inc, a group of peers worth examining would be PRTA, PLXP, KROS, VTVT, and SNDX.
  • LPCN's SEC filings can be seen here. And to visit Lipocine Inc's official web site, go to

LPCN Valuation Summary

  • LPCN's EV/EBIT ratio is -5.8; this is 119.8% lower than that of the median Healthcare stock.
  • LPCN's price/sales ratio has moved NA NA over the prior 96 months.
  • LPCN's price/sales ratio has moved NA NA over the prior 96 months.

Below are key valuation metrics over time for LPCN.

Stock Date P/S P/B P/E EV/EBIT
LPCN 2021-08-31 NA 3.2 -6.1 -5.8
LPCN 2021-08-30 NA 3.3 -6.3 -6.0
LPCN 2021-08-27 NA 3.3 -6.2 -5.9
LPCN 2021-08-26 NA 3.3 -6.2 -5.9
LPCN 2021-08-25 NA 3.5 -6.5 -6.2
LPCN 2021-08-24 NA 3.5 -6.6 -6.3

LPCN Growth Metrics

    Its 3 year price growth rate is now at -79.14%.
  • Its year over year revenue growth rate is now at -100%.
  • Its 3 year net cashflow from operations growth rate is now at 39.83%.
LPCN's revenue has moved up $16,140,838 over the prior 34 months.

The table below shows LPCN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 16.14084 -4.411303 -0.634399
2021-09-30 0.054994 -17.08987 -17.7697
2021-06-30 0 -14.27264 -19.00166
2021-03-31 0 -15.98861 -18.56225
2020-12-31 0 -15.3031 -20.96482
2020-09-30 0 -14.92711 -19.74562

LPCN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LPCN has a Quality Grade of D, ranking ahead of 21.42% of graded US stocks.
  • LPCN's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
  • ZTS, MDWD, and GERN are the stocks whose asset turnover ratios are most correlated with LPCN.

The table below shows LPCN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 NA -1.022
2021-03-31 0.000 NA -1.500
2020-12-31 0.000 NA -4.723
2020-09-30 0.000 NA -3.288
2020-06-30 0.008 1 -2.946
2020-03-31 0.008 1 -1.844

LPCN Price Target

For more insight on analysts targets of LPCN, see our LPCN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.75 Average Broker Recommendation 1.33 (Strong Buy)

LPCN Stock Price Chart Interactive Chart >

Price chart for LPCN

LPCN Price/Volume Stats

Current price $0.82 52-week high $1.89
Prev. close $0.82 52-week low $0.71
Day low $0.82 Volume 145,864
Day high $0.85 Avg. volume 624,932
50-day MA $0.87 Dividend yield N/A
200-day MA $1.09 Market Cap 72.86M

Lipocine Inc. (LPCN) Company Bio

Lipocine develops pharmaceutical products using its oral drug delivery technology in the areas of men’s and women’s health, with a current focus being testosterone replacement. The company was founded in 1997 and is based in Salt Lake City, Utah.

LPCN Latest News Stream

Event/Time News Detail
Loading, please wait...

LPCN Latest Social Stream

Loading social stream, please wait...

View Full LPCN Social Stream

Latest LPCN News From Around the Web

Below are the latest news stories about Lipocine Inc that investors may wish to consider to help them evaluate LPCN as an investment opportunity.

Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Yahoo | February 25, 2022

Lipocine announces FDA accepted the marketing application for Tlando

Lipocine <> shares are trading higher after announcing that the FDA accepted the New Drug Application ("NDA") resubmission for Tlando (testosterone undecanoate), a potential rival

Seeking Alpha | February 3, 2022


Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products for metabolic and endocrine disorders, today announced that Antares Pharma, Inc. issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has accepted its New Drug Application ("NDA") resubmission for TLANDO® (testosterone undecanoate). The FDA designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target action date of

Yahoo | February 3, 2022

Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO®

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the peer-reviewed publication of positive Phase 3 clinical data from the Dosing Validation ("DV") study which evaluated the fixed-dose oral testosterone undecanoate, TLANDO, for the treatment of hypogonadism. As previously disclosed, the DV study met its primary endpoint, with TLANDO restoring testosterone levels to the normal range in hypogonadal males. The pape

Yahoo | January 27, 2022

Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that one abstract has been selected for podium presentation and three abstracts have been selected for poster presentations during the upcoming 2022 NASH-TAG Conference in Park City, Utah on January 6-8, 2022.

Yahoo | January 5, 2022

Read More 'LPCN' Stories Here

LPCN Price Returns

1-mo -4.66%
3-mo -38.35%
6-mo -18.81%
1-year -43.06%
3-year -57.95%
5-year -79.90%
YTD -17.26%
2021 -27.13%
2020 253.34%
2019 -70.39%
2018 -62.21%
2017 -6.52%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4829 seconds.